T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Travere Therapeutics
TVTX
$5.79B
| $240K | ﹤0.01% |
31,009
+2,948
| +11% | +$24.9K |
|
2527
Lineage Cell Therapeutics
LCTX
$268M
| $239K | ﹤0.01% |
161,314
+70,418
| +77% | +$79.8K |
|
2528
Cogent Biosciences
COGT
$6.47B
| $237K | ﹤0.01% |
35,211
+4,030
| +13% | +$24.9K |
|
2529
Blink Charging
BLNK
$87.1M
| $236K | ﹤0.01% |
78,171
+13,402
| +21% | +$37.8K |
|
2530
American Well
AMWL
$220M
| $235K | ﹤0.01% |
14,466
+6,222
| +75% | +$133K |
|
2531
Clearfield
CLFD
$390M
| $233K | ﹤0.01% |
7,536
+510
| +7% | +$14.6K |
|
2532
Cytek Biosciences
CTKB
$636M
| $233K | ﹤0.01% |
34,665
+3,987
| +13% | +$31.5K |
|
2533
Marcus & Millichap
MMI
$1.2B
| $233K | ﹤0.01% |
6,795
+767
| +13% | +$28.1K |
|
2534
Park-Ohio Holdings
PKOH
$718M
| $233K | ﹤0.01% |
8,703
+449
| +5% | +$11.4K |
|
2535
Bank First Corp
BFC
$1.76B
| $232K | ﹤0.01% |
+2,676
| New | +$226K |
|
2536
Seres Therapeutics
MCRB
$45M
| $232K | ﹤0.01% |
14,906
-3,277
| -18% | -$70.7K |
|
2537
Avita Medical
RCEL
$248M
| $232K | ﹤0.01% |
14,459
+1,117
| +8% | +$18.1K |
|
2538
1-800-Flowers.com
FLWS
$261M
| $231K | ﹤0.01% |
21,265
+1,287
| +6% | +$13.2K |
|
2539
Nordic American Tanker
NAT
$1.4B
| $231K | ﹤0.01% |
58,791
+8,985
| +18% | +$37.7K |
|
2540
Ranpak Holdings
PACK
$479M
| $231K | ﹤0.01% |
29,268
+2,191
| +8% | +$11.5K |
|
2541
iShares Russell 3000 ETF
IWV
$20.6B
| $230K | ﹤0.01% |
764
| – | – |
|
|
CNSL
2542
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $230K | ﹤0.01% |
53,012
+4,535
| +9% | +$19.7K |
|
2543
American Superconductor
AMSC
$1.53B
| $229K | ﹤0.01% |
16,911
| – | – |
|
2544
The Joint Corp
JYNT
$119M
| $229K | ﹤0.01% |
17,464
+837
| +5% | +$8.66K |
|
|
FBMS
2545
DELISTED
The First Bancshares, Inc.
FBMS
| $229K | ﹤0.01% |
8,797
+1,332
| +18% | +$34.2K |
|
2546
Smith & Wesson
SWBI
$643M
| $228K | ﹤0.01% |
13,111
+1,952
| +17% | +$28.2K |
|
|
SBOW
2547
DELISTED
SilverBow Resources, Inc.
SBOW
| $227K | ﹤0.01% |
+6,644
| New | +$193K |
|
2548
Hingham Institution for Saving
HIFS
$686M
| $225K | ﹤0.01% |
1,286
+101
| +9% | +$17.8K |
|
2549
Kelly Services Class A
KELYA
$566M
| $225K | ﹤0.01% |
+8,975
| New | +$201K |
|
|
FIRY
2550
Firy Inc
FIRY
$158M
| $225K | ﹤0.01% |
34,592
+4,800
| +16% | +$29.5K |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.